SunBio,Inc.
Financials
Valuation Metrics
SunBio,Inc.'s Market Cap is ₩704B. At end of 2025 it was ₩694B. Ranked #1539 of 2,421 in KR market (top 64%), #905 of 1,640 on KOSDAQ (top 55%), #168 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 73%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 70.35B KRW | KR#1,539/2,421 Sec#168/231 |
| Revenue | 12.45B KRW | KR#2,256/2,421 Sec#171/231 |
| Net Income | 4.31B KRW | KR#1,258/2,421 Sec#87/231 |
| Total Assets | 64.17B KRW | KR#2,067/2,421 Sec#177/231 |
| Net Assets | 29.96B KRW | KR#2,177/2,421 Sec#195/231 |
| Employees | 23 | KR#2,239/2,421 Sec#210/231 |
| Value | ||
| P/E | 16.31x | KR#1,085/2,421 Sec#65/231 |
| P/B | 2.35x | KR#2,015/2,421 Sec#152/231 |
| PEG | 0.02x | KR#199/2,421 Sec#9/231 |
| P/S | 5.65x | KR#2,174/2,421 Sec#145/231 |
| EV/EBITDA | 21.72x | KR#1,049/2,421 Sec#63/231 |
| FCF Yield | 0.82% | KR#1,153/2,421 Sec#84/231 |
| Profitability | ||
| ROE | 14.40% | KR#348/2,421 Sec#24/231 |
| ROA | 6.72% | KR#546/2,421 Sec#43/231 |
| Op. Margin | 35.90% | KR#34/2,421 Sec#7/231 |
| Revenue Growth | 25.12% | KR#453/2,421 Sec#44/231 |
| Earnings Growth | 732.15% | KR#81/2,421 Sec#6/231 |
| Financial Health | ||
| Debt Ratio | 114.16% | KR#1,666/2,421 Sec#191/231 |
| Total Debt | 30.62B KRW | KR#1,220/2,421 Sec#91/231 |
| FCF | 576.6M KRW | KR#1,172/2,421 Sec#88/231 |
| Cash | 3.87B KRW | KR#2,098/2,421 Sec#197/231 |
| Current Ratio | 0.46x | KR#2,160/2,421 Sec#210/231 |
| Net Debt/EBITDA | 5.98x | KR#1,082/2,421 Sec#81/231 |
| Performance | ||
| 1Y Return | -9.00% | KR#949/2,421 Sec#60/231 |
| 1M Return | -5.26% | KR#1,813/2,421 Sec#145/231 |
| From 52W High | -32.24% | KR#612/2,421 Sec#37/231 |
| 1Y MDD | -31.73% | KR#303/2,421 Sec#21/231 |
| Trading | ||
| Volume | 6,149 shares | KR#2,075/2,421 Sec#198/231 |
| Trading Value | 35.5M KRW | KR#1,956/2,421 Sec#200/231 |
| Foreign Own. | 0.32% | KR#2,253/2,421 Sec#216/231 |
| Per Share | ||
| EPS | 353 KRW | KR#1,105/2,421 Sec#77/231 |
| BPS | 2,453 KRW | KR#1,965/2,421 Sec#157/231 |
Company Info
Seonbio, established in 1997 and listed on KOSDAQ in 2022 as a technology growth company, specializes in the research, development, production, and sales of biopharmaceuticals, medical devices, and PEG derivatives. Utilizing its PEGylation technology, the company has commercialized various biopharmaceuticals, biosimilar drugs, and medical devices. Its neutropenia treatment Pegfilgrastim biosimilar is sold in the EU, Canada, Australia, and India, while the dry mouth treatment MucoPEG received US FDA sales approval in 2019.